Emergent BioSolutions Q2 FY26 net loss widens to $180.2 million; revenue rises 66% to $234.3 million
EBS•Updated full-year outlook
Emergent cut its full-year revenue outlook to $645 million-$675 million from $720 million-$760 million; it projected a GAAP net loss of $245 million-$225 million.
Revenue by product category
Naloxone revenue fell 22% to $52.4 million, while smallpox MCM revenue more than doubled to $101.6 million; other products revenue rose to $54.1 million.
Restructuring and cost savings
The company launched an organizational restructuring expected to deliver about $40 million in annualized savings, including a reduction of about 90 roles and a new Growth organization.
Revenue and profitability in Q2 FY26
Emergent BioSolutions posted Q2 revenue of $234.3 million, up 66% year over year; GAAP net loss widened to $180.2 million on a .
